Development of a prognostic model based on immunogenic cell death/ferroptosis-related genes and the study of TREX1 effects on prostate cancer cells.

Collectively, these findings indicate that TREX1, NOX4, and RRM2 may be significant contributors to the progression of prostate cancer; however, their precise roles and potential therapeutic implications warrant further investigation.

also in 13,097 other papers

The PARP inhibitor ABT-888 (Veliparib) showed a trend toward increased activity, with case reports and early-phase studies suggesting that tumors harboring homologous recombination repair deficiencies, particularly BRCA2 alterations, may be more susceptible; however, evidence in prostate cancer remains limited ( 31 ).

also in 53,322 other papers